The ARK Genomic Revolution ETF is a thematic exchange-traded fund focused on companies involved in the development and application of innovative technologies in genomics and biotechnology. This includes firms operating in areas such as DNA sequencing, gene therapy, bioinformatics, molecular diagnostics, and personalized medicine. The ETF is actively managed by ARK Invest under the leadership of Cathie Wood, aiming to identify breakthrough technologies and high-growth companies with strong innovation potential. It is suitable for investors seeking long-term growth in the biotechnology sector, though it comes with higher volatility and risk.
Feed
There are no posts to show right now.
Używamy ciasteczek, aby ulepszyć Twoje doświadczenie na naszej stronie.
